Hematopoietic Stem Cell Transplantation in India-2017 Annual Update

Rapid advances are being made in the field of plasma cell dyscrasias. Many abstracts pertaining to the laboratory aspects, clinical features, treatment modalities and outcome of plasma cell dyscrasias were presented at Hematocon 2017. All the total of 24 abstracts pertaining to plasma cell dyscrasias presented at the Hematocon 2017 were reviewed. Out of them 10 were original research and 14 were case reports/short case series. The key findings of original research studies conducted in India are being summarized. Exciting research in the field of plasma cell dyscrasias is being carried out by various centers in the country. Data presented on various aspects of research in plasma cell disorders is encouraging. Multicentric research in the field plasma cell dyscrasias should be encouraged to highlight the various aspects of disease biology and challenges in management unique to our country.

show abstract

“…Case reports and short case series were excluded from the analysis. Data pertaining to stem cell transplant is reviewed elsewhere [1].…”

Section: Methodsmentioning

confidence: 99%

Plasma Cell Dyscrasias in India-2017 Updates

Jain

Malhotra

2017

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

show abstract

“…FLAG ( udarabine cytarabine + G-CSF) is the most used induction therapy for the treatment of Acute myeloid leukemia patients (7,8). Other interventions include Monoclonal antibody therapy, HSCT (Hematopoietic stem cell transplantation), and CAR T cell therapy (9)(10)(11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Evaluating the Multifaceted Impact of Induction Therapy on HbA1c, Quality of Life, Infection Risk, and TNF Levels in Acute Leukemia Patients

Chaudhary,

Karhana,

Bhurani

et al. 2024

Preprint

View full text Add to dashboard Cite

Aim The cross-sectional study aimed to evaluate the effect of induction chemotherapy on HbA1c levels in non-diabetic Acute leukaemia patients and its association with risk of infection and Quality of Life.Methods The study involved four groups with distinct timelines for sample collection, i.e. before induction chemotherapy, within 7 days, within 14 days, and within 30 days after treatment initiation. Participants were screened based on specific criteria, and written informed consent was obtained. Quality of life, glycated haemoglobin (HbA1C), and TNF alpha levels were assessed.Results The second week following the initiation of induction therapy for acute leukemia is characterized by elevated levels of TNF alpha, and increased risk of infection. However, these parameters tend to normalize after approximately 30 days of commencing the induction therapy. No significant change in HbA1c was observed between the initiation of induction therapy and 30 days after initiation. Additionally, a weak positive correlation between HbA1c and TNF alpha was observed (r = 0.072, p > 0.05), suggesting a non-significant association between blood sugar levels and inflammation. Quality of life assessments showed that patients experienced notably improved overall health outcomes within 30 days of treatment initiation while exhibiting significantly higher global and functional scores on the EORTC QLQ C30 scale.Conclusion During the initial stages of chemotherapy for acute leukemia, it is crucial for medical professionals to consistently monitor the blood glucose levels and the presence of infections in patients and provide appropriate interventions as needed.

show abstract

“…According to Indian stem cell transplant registry (ISCTR) Nov 2017 report, total of 1878 transplants were performed in around 52 HSCT centres across India [3]. The recent developments in the area of HSCT has shown no short-term mortalities in India which is an encouraging outcome that will boost establishment of new bone marrow transplant centres across India [3][4][5][6][7]. The present study aimed to describe the clinical characteristics and outcomes of patients with malignant and non-malignant disorders who underwent HSCT at SMS Hospital.…”

Section: Introductionmentioning

confidence: 99%

Hematopoietic stem cell transplantation Experience : A Retrospective analysis from largest center of India’s largest state

Jasuja

Kumar

Mittal

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective: The present study aimed to describe the clinical characteristics and outcomes of patients with malignant and non-malignant disorders who underwent hematopoietic stem cell transplantation at largest public Hospital of Rajasthan, India. Methods: This was a retrospective study conducted at the Department of Medical oncology & Stem cell transplant, SMS hospital, Jaipur, India. The study included patients of either sex who had underwent any type of Hematopoietic stem cell transplantation during 2009 to June 2021. Data collected for retrospective observational analysis included demographic and clinical details including age, sex, clinical diagnosis, type of transplant, time of transplant, treatment regimen, status at transplant, acute/chronic GVHD, date of discharge/last follow-up/death, clinical outcome, and cause of death. Results: Total of 100 patients which underwent HSCT from initiation of transplant in 2009 at our Center to June 2021 were included (mean age: 29.9 years). Out of 100 patients, 49% of patients underwent autologous transplantation, while 51% underwent allogeneic transplantation during this period. Out of 51% of patients which underwent allogeneic transplant, 17.6% were haploidentical stem cell transplant. The most common malignancies for which patients underwent HSCT at our center was multiple myeloma (29.0%), followed by aplastic anemia (24.0%), and Hodgkin’s lymphoma (12.0%). Other diseases for which patients underwent HSCT at our center are Non-Hodgkin lymphoma, amyloidosis, multiple sclerosis, Thalassemia, germ cell tumor, chronic myeloid leukemia, Acute Myeloid leukemia, Myelodysplastic syndrome, Neuroblastoma, dyskeratosis congenita ,primary CNS lymphoma and congenital dyserythropoietic anemia type 2.Majority of patients which underwent stem cell transplant were in complete remission (82%) at the time of transplant. Acute graft versus host disease (GvHD) was observed in 80% of patients while 11.8% of patients reported chronic GvHD in allogeneic Hematopoietic stem cell transplant. Total of 84 patients survived while 16 patients died post-transplant. Majority of patients died due to infection (60.0%) and GvHD (20.0%). The overall mean survival time was 1540 days at the time of data analysis. The mean survival time in patients with allogenic transplants was significantly higher than those with autologous transplant (1907.2 vs. 452.3 days; p=0.042). Conclusion: With overall higher survival rate and overall mean survival of more than four years, HSCT in Indian settings may be considered as a promising treatment for patients with benign or malignant diseases.

show abstract

Hematopoietic Stem Cell Transplantation in India-2017 Annual Update

Cited by 6 publications

References 7 publications

Plasma Cell Dyscrasias in India-2017 Updates

Plasma Cell Dyscrasias in India-2017 Updates

Evaluating the Multifaceted Impact of Induction Therapy on HbA1c, Quality of Life, Infection Risk, and TNF Levels in Acute Leukemia Patients

Hematopoietic stem cell transplantation Experience : A Retrospective analysis from largest center of India’s largest state

Contact Info

Product

Resources

About